Client News

[GlobeNewswire] - RUTHERFORD, N.J., Feb. 08, 2016-- Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announces that President and CEO Panna Sharma is ...
Posted: February 8, 2016, 2:21 pm
[Business Wire] - Aurinia Pharmaceuticals Inc. announced today that it has completed a preliminary analysis of its AURION study.
Posted: February 8, 2016, 1:30 pm
[PR Newswire] - Carl Spana, Ph.D., President and CEO of Palatin, commented, "The allowed patent is significant because it applies specifically to methods of treatment of female sexual dysfunction consistent with our projected approved product. Once issued, the patent is expected to expire no earlier than November 2033, and will further enhance Palatin's key bremelanotide patent family, which includes U.S. Patent Nos.
Posted: February 8, 2016, 12:30 pm
[PR Newswire] - NEW YORK, Feb. 8, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper, Chief Executive Officer, will be presenting at the 18th annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 5:30 PM local time at the Waldorf Astoria, Conrad Room, in New York. Dr. Daniel Teper, CEO of Immune, will provide an overview of the Company's business and 2016 expected milestones, including updates on the advancement of the two Phase 2 clinical trials with bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, and information on the company's immuno-oncology pipeline. Immune Pharmaceuticals (IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
Posted: February 8, 2016, 12:30 pm
[PR Newswire] - TORONTO, Feb. 5, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, February 9th, 2016 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (888) 227-6492 (North America) and (303) 223-2685 (International). A webcast is also available at www.transitiontherapeutics.com. A replay of the conference call will be available on Transition's website for seven days following the call.
Posted: February 5, 2016, 6:01 pm
[CNW Group] - Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST
Posted: February 5, 2016, 6:01 pm
[GlobeNewswire] - RUTHERFORD, N.J.& LOS ANGELES, Feb. 05, 2016-- Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed ...
Posted: February 5, 2016, 1:00 pm
[Business Wire] - Aurinia Pharmaceuticals Inc., today announced that its Chief Operating Officer Michael R. Martin will attend two upcoming investor conferences. A general corporate overview will be provided in presentation format during the Source Capital 2016 Disruptive Growth & Healthcare Conference on February 10th, 2016, while a fireside chat & discussion will occur at the 5th Annual Leerink Global Healthcare Conference ...
Posted: February 4, 2016, 9:30 pm
[GlobeNewswire] - DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel ...
Posted: February 4, 2016, 9:07 pm
[GlobeNewswire] - DUBLIN, Ireland, Feb. 04, 2016-- Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced ...
Posted: February 4, 2016, 9:05 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. , announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Monday, February 8, 2016 at 1:00 PM ET at the 2016 BIO CEO & Investor Conference.
Posted: February 4, 2016, 2:21 pm
[GlobeNewswire] - NEW YORK -- Stemline Therapeutics, Inc. , announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 4:00 PM ...
Posted: February 4, 2016, 1:00 pm
[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 4, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 10:00 a.m. EST in New York, NY. Jeffrey Bacha, DelMar's president and CEO, will provide an update on the ongoing clinical trial of VAL-083 (dianhydrogalactitol) in patients with recurrent glioblastoma multiforme (GBM) as well as discuss the Company's goal to "up-list" its shares to a National U.S. Exchange.
Posted: February 4, 2016, 12:35 pm
[PR Newswire] - CRANBURY, N.J., Feb. 4, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 18 th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology ...
Posted: February 4, 2016, 12:30 pm
[Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company’s novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors.
Posted: February 4, 2016, 12:00 pm